Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 92.48% is 18% above its 5-year average of 78.62%, near the high end of its 5-year range (40.92%–94.16%).
1.40% above its 12-month average of 91.20%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 93.27%.
GROSS MARGIN
92.48%
GROSS MARGIN AVG TTM
91.20%
GROSS MARGIN AVG 3Y
74.96%
GROSS MARGIN AVG 5Y
78.62%
GROSS MARGIN AVG 10Y
81.26%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.40%
CURRENT VS 3Y AVG
+23.38%
CURRENT VS 5Y AVG
+17.63%
CURRENT VS 10Y AVG
+13.81%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
38.44%
median of 682 covered companies
CURRENT VS SECTOR MEDIAN
+140.58%
vs the sector median at left
Liquidia Corporation
Market Cap
$2.36B
Gross Margin
92.48%
TTM Avg
91.20%
3Y Avg
74.96%
5Y Avg
78.62%
Market Cap
$2.38B
Gross Margin
77.55%
TTM Avg
-114.38%
3Y Avg
-188.02%
5Y Avg
-219.43%
Market Cap
$2.38B
Gross Margin
64.71%
TTM Avg
54.44%
3Y Avg
41.55%
5Y Avg
20.41%
Market Cap
$2.32B
Gross Margin
75.42%
TTM Avg
77.61%
3Y Avg
78.83%
5Y Avg
79.96%
Market Cap
$2.41B
Gross Margin
18.57%
TTM Avg
22.55%
3Y Avg
18.71%
5Y Avg
13.63%
Market Cap
$2.43B
Gross Margin
-61.96%
TTM Avg
-19.42%
3Y Avg
-14.39%
5Y Avg
23.74%
Market Cap
$2.29B
Gross Margin
17.98%
TTM Avg
29.88%
3Y Avg
47.29%
5Y Avg
57.26%
Market Cap
$2.42B
Gross Margin
56.20%
TTM Avg
28.10%
3Y Avg
28.10%
5Y Avg
28.10%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liquidia Corporation (LQDA) | $2.36B | 92.48% | 91.20% | 74.96% | 78.62% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.38B | 77.55% | -114.38% | -188.02% | -219.43% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.38B | 64.71% | 54.44% | 41.55% | 20.41% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.32B | 75.42% | 77.61% | 78.83% | 79.96% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.41B | 18.57% | 22.55% | 18.71% | 13.63% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.43B | -61.96% | -19.42% | -14.39% | 23.74% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.29B | 17.98% | 29.88% | 47.29% | 57.26% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.42B | 56.20% | 28.10% | 28.10% | 28.10% |
| Disc Medicine, Inc. (IRON)vs › | $2.47B | 0.00% | 0.00% | 0.00% | 0.00% |
| Pharvaris N.V. (PHVS)vs › | $2.16B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
92.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 93.27% |
| 2026-03-31 | 90.86% |
| 2025-12-31 | 92.33% |
| 2025-09-30 | 94.16% |
| 2025-06-30 | 85.38% |
| 2025-03-31 | 51.38% |
| 2024-12-31 | 53.58% |
| 2024-09-30 | 64.82% |
| 2024-06-30 | 59.20% |
| 2024-03-31 | 40.92% |
| 2023-12-31 | 78.08% |
| 2023-09-30 | 84.50% |
| 2023-06-30 | 85.98% |
| 2023-03-31 | 85.44% |
| 2022-12-31 | 87.05% |
| 2022-09-30 | 76.62% |
| 2022-06-30 | 81.34% |
| 2022-03-31 | 80.13% |
| 2021-12-31 | 77.42% |
| 2021-09-30 | 72.00% |
| 2021-06-30 | 78.85% |
| 2021-03-31 | 77.50% |
| 2020-12-31 | 67.86% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 90.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | -21235.18% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 90.95% |
| 2018-03-31 | 97.08% |
| 2017-12-31 | 95.60% |
| 2017-09-30 | 95.61% |
| 2017-06-30 | 95.97% |
| 2017-03-31 | 95.12% |
